Link: https://www.celgene.com/?%2Fpatients%2F
Description: WebLearn how Celgene, a global biopharmaceutical company, is committed to improving the lives of patients worldwide by delivering truly innovative and life-changing treatments. Explore the therapies for Hematology, Oncology, Inflammation and Immunology and the medical research to help people live longer, better, and healthier.
DA: 1 PA: 9 MOZ Rank: 14
Link: https://www.bms.com/patient-and-caregivers/our-medicines.html
Description: Web1-800-721-5072. (toll free U.S. only) Report side effects or product quality complaints about legacy celgene products (ABRAXANE®, IDHIFA®, INREBIC®, ISTODAX®, POMALYST®, REBLOZYL®, REVLIMID®, THALOMID®, VIDAZA®) Learn more >. Below is a list of our company's marketed products.
DA: 43 PA: 82 MOZ Rank: 42
Link: https://en.wikipedia.org/wiki/Celgene
Description: WebCelgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias.
DA: 49 PA: 68 MOZ Rank: 67
Link: https://www.revlimid.com/
Description: WebREVLIMID is a prescription medicine, used to treat adults with multiple myeloma (MM) in combination with the medicine dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation (a type of stem cell transplant that uses your own stem cells).
DA: 21 PA: 31 MOZ Rank: 10
Link: https://news.bms.com/news/corporate-financial/2019/Bristol-Myers-Squibb-Completes-Acquisition-of-Celgene-Creating-a-Leading-Biopharma-Company/default.aspx
Description: WebNov 20, 2019 · NEW YORK-- ( BUSINESS WIRE )--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by …
DA: 8 PA: 67 MOZ Rank: 51
Link: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma
Description: WebMarch 27, 2021. The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded...
DA: 74 PA: 39 MOZ Rank: 75
Link: https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-and-bluebird-bios-Abecma-idecabtagene-vicleucel-the-First-Anti-BCMA-CAR-T-Cell-Therapy-for-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx
Description: WebMar 26, 2021 · Bristol Myers Squibb - U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma.
DA: 23 PA: 31 MOZ Rank: 87
Link: https://s21.q4cdn.com/104148044/files/doc_presentations/2019/BMY-Transaction-Fact-Sheet-03-25-19-01074879-8xA26CA.PDF
Description: WebStreet estimates for Celgene’s pipeline revenue as early as 2023 are ~$5Bn, which at industry multiples implies substantial value creation. These products will continue to grow as they achieve peak sales in excess of their ~$5Bn sales in 2023.
DA: 94 PA: 75 MOZ Rank: 21
Link: https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Acquire-Celgene-to-Create-a-Premier-Innovative-Biopharma-Company/default.aspx
Description: WebJan 3, 2019 · NEW YORK & SUMMIT, N.J.,--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately …
DA: 75 PA: 57 MOZ Rank: 27
Link: https://media.celgene.com/content/uploads/2014/02/Celgene_Brochure.pdf
Description: WebCelgene products which enhance their quality of life.” Darren H., Finance (Melbourne, AU – Asia Pacific) “We have all of the pieces to the puzzle – team chemistry, hard-working people, genuine belief in our products, and strong company values.” Deborah S., Field Salesforce (USA) Global reach Celgene employs some of the
DA: 46 PA: 89 MOZ Rank: 26
